Trial reportAesthetic plastic surgery2026
A Prospective, Randomized, Active-Controlled, Evaluator-Blinded, Noninferiority Clinical Trial Examining a Non-Cross-Linked Bovine-Derived Type I/III Collagen Filler Combined with Hyaluronic Acid for Periocular Rejuvenation.
Trial report in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cannula Gauge and Tissue Penetration Forces in the Temporal Region: A Biomechanical Basis for Injection Safety.Aesthetic plastic surgery · 2026Article
- Comment on "Increasing Facial Attractiveness by Lateralizing the Auricle: Analyzing the Pan-Facial Effects of the Postauricular Injection Technique in Chinese Patient Populations".Aesthetic plastic surgery · 2026Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of dermal fillers for periocular rejuvenation is common, with hyaluronic acid (HA) being the most popular agent. However, the use of HA in the delicate tear trough region may induce the Tyndall effect, resulting in undesirable bluish discoloration of the lower eyelid. The main drawback of collagen monotherapy is its relatively short effective duration. In this study, FILLDERM
objectivesThis study evaluated the efficacy and safety of combining collagen with HA for moderate periocular aging. This combination approach was compared with HA and collagen monotherapies.
methodsPatients were randomized to receive (1) HA alone, (2) collagen alone, or (3) a combination of HA and collagen via our standardized dual-plane injection protocol (3 sharp-needle periosteal injections + 1 cannula subdermal injection). The treatment outcomes were assessed using the Allergan Infraorbital Hollow Scale (AIHS), the Global Aesthetic Improvement Scale (GAIS), and standardized photographic evaluation at multiple follow-ups.
resultsCompared with monotherapies, the combination therapy yielded superior outcomes in terms of periocular volume restoration and longevity. The combination therapy effectively addressed both structural support (via periosteal injections) and superficial rejuvenation (via subdermal placement) while significantly reducing the incidence of the Tyndall effect in the HA monotherapy group. The combination therapy showed extended durability compared with collagen monotherapy.
conclusionsThe combination of collagen and HA offers a comprehensive approach for periocular rejuvenation. This method combines the volumizing benefits of HA with the tissue-regenerative properties of collagen. Furthermore, this approach minimizes complications while enhancing treatment longevity, thus establishing a new standard for minimally invasive periocular rejuvenation. LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.